Cost and clinical outcomes of @entity4037 repair using intraperitoneal nonheavyweight XXXX mesh.

@entity1 @entity154 @entity7502 @entity702 @entity736 @entity1744 @entity4037
BACKGROUND: There are a variety of different products available for @entity4037 repairs (LVHR), which vary widely in their costs. There are few clinical studies commenting on cost efficacy of LVHR. The objective of this study is to investigate the cost, safety, and efficacy of using intraperitoneal nonheavyweight @entity7502 (PP) mesh in LVHR. METHODS: Between the years 2002 and 2006, LVHR was performed in 141 consecutive @entity1 (84 male, 57 female) using intraperitoneal PP. Using a 3-trocar technique, PP mesh was underlayed by 3 to 5 cm beyond the edges of the @entity154 and fixed to the abdominal wall with 2 rows of @entity702 staples. Data concerning the demographics of @entity1 , mesh cost, operative time, length of hospital stay, and complications were collected. RESULTS: One hundred thirty-four @entity1 (95%) were discharged on the day of surgery. Mean age was 58.7 years (range, 29 to 91 y). Mean operative time was 63 minutes (range, 34 to 124 min). Follow-up was achieved in 123 @entity1 (87%) with a mean of 40 months (range, 12 to 68 mo). The average mesh size was 256.9 cm (range, 116 to 903 cm). The cost of the PP mesh was US 0.14 per cm. The average mesh cost per @entity1 was  35.90. When compared with other meshes commonly used for LVHR, PP mesh was substantially cheaper with a cost saving of  436 per @entity1 with proceed,  770 per @entity1 with composix, and  931 per @entity1 with @entity736 . The postoperative complications included: Wound infection n=4 (3.2%), transient @entity1744 which resolved in all cases without operative management n=3 (2.4%), port site hernia n=2 (1.6%), and seroma n=1 (0.7%). Overall recurrence rate was n=6 (4.8%). There were no conversions to an open procedure. CONCLUSIONS: LVHR with intraperitoneal PP results in outcomes comparable with earlier publications on LVHR but at reduced costs. These data suggest that the use of intraperitoneal PP in LVHR is safe and cost effective.
